Tradjenta (linagliptin) is a diabetes drug that is linked to pancreatic cancer, pancreatitis, rhabdomyolysis, and other serious side effects.
Do I Have a Texas Tradjenta Lawsuit? Collen A. Clark is a true advocate for his clients and is passionate about helping Texans that have been injured or wronged. If you or a loved one was diagnosed with a severe side effect, you should contact our lawyers immediately. You may be entitled to compensation by filing a lawsuit.
Tradjenta Side Effects
- Bile duct disease
- Bullous pemphigoid
- Gallbladder disease
- Joint pain
- Pancreatic cancer and pancreatitis
FDA Evaluating Rhabdomyolysis Risk
The FDA is evaluating a potential signals of a serious risk and new safety information linking DPP4 diabetes drugs and rhabdomyolysis. This potentially life-threatening kidney side effect was identified by the FDA Adverse Event Reporting System (FAERS) between April and June 2017.
FDA Warnings for Tradjenta
August 28, 2015 — The FDA has issued a Safety Communication about the risk of severe, disabling joint pain from Tradjenta. Click here to read more.
March 14, 2013 — Safety Communication for Tradjenta and Incretin Mimetic Drugs. The FDA is investigating findings that suggest an increased risk of pancreatitis and pre-cancerous cellular changes in the pancreas. Click here to read more.
What is Tradjenta?
Tradjenta (linagliptin) is an oral type-2 diabetes treatment that regulates insulin levels and helps improve blood-sugar control. It works by inhibiting dipeptidyl peptidase-4 (DPP-4), which decreases the amount of glucose (sugar) released into the bloodstream and stimulates the release of insulin, a hormone that lowers blood-sugar levels.
Boehringer Ingelheim received approval for Tradjenta in August 2012. It is one of the newest drugs in a class of anti-diabetes medications that work by influencing digestive hormones (also known as incretins), such as GLP-1 and/or DPP-4. These drugs are collectively known as “incretin mimetics.”
What is the problem with Tradjenta?
Tradjenta has only been sold in the U.S. since 2012, and it belongs to a class of drugs that was introduced in 2006. Therefore, the long-term risks of using Tradjenta to treat type-2 diabetes are not fully understood. The problem is that there is already a growing amount of research suggesting that all drugs in the incretin mimetic class may increase a patient’s risk of pancreatitis or pancreatic cancer. These are extremely severe, life-threatening side effects.
Tradjenta and Pancreatic Cancer
The Prescribing Information for Tradjenta already warns about a potential risk of pancreatitis (pancreatic inflammation), which was identified in clinical trials. Unfortunately, because pancreatitis is a risk-factor for pancreatic cancer, there is growing concern that Tradjenta and other incretin mimetic drugs may also increase the risk of cancer.
To investigate this risk, researchers autopsied pancreases from eight people with diabetes who used an incretin mimetic drug and compared the organs to people who did not use the drugs. The results of their study were published in Diabetes in March 2013.
Unfortunately, the researchers found striking evidence of pancreatitis, and three out of eight pancreases had benign tumors called adenomas, which can become malignant. One patient who was taking Januvia had a tumor in the pancreatic duct. The researchers warned about an increased risk of pancreatic surgery, which would make a patient dependent on insulin:
“Since the standard of care of a pancreatic neuroendocrine tumor, because of the risk of conversion to malignancy, even if benign, is surgical resection [i.e. removal], patients exposed to incretin therapy would seem to be at increased risk of requiring pancreatic surgery.”
Tradjenta Class Action Lawyer
The Clark Firm, LLP is nationally recognized as a class action law firm. However, we are not filing a Tradjenta class action at this time. Instead, we are filing individual lawsuits on behalf of people who were diagnosed with severe side effect. Hundreds of lawsuits have been filed by people who took diabetes drugs in the incretin mimetic class. As of January 2016, over 750 lawsuits were consolidated in federal court in California in Multi-District Litigation (MDL No. 2452).
Need a Tradjenta Lawyer in Texas?
Collen A. Clark is a true advocate for his clients and is passionate about helping Texans that have been injured or wronged.
Collen’s amazing success in the courtroom and well known dedication to his clients has earned him the recognition of his peers as one of The Top Trial Lawyers in Texas.”
The Clark Firm has assembled a team of trial lawyers with more than 100 years experience, participation in over 600 jury trials and $260 million in verdicts and/or settlements. Please use the form below to contact us for a free Texas Tradjenta lawsuit review.